Price T Rowe Associates Inc Akero Therapeutics, Inc. Call Options Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AKRO
# of Institutions
190Shares Held
74.4MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$199 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$178 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$149 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$140 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$132 Million4.29% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.17B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...